title: O-phospho-L-serine: a modulator of bone healing in calcium-phosphate cements.
abstract: Bone substitution materials are seen as an alternative to autogenous bone transplants in the reconstruction of human bone structures. The aim of the present animal study was to evaluate the clinical handling and the conditions of bone healing after the application of a phosphoserine and collagen-I-modified calcium-phosphate cement (Biozement D). The application of phosphoserine is supposed to influence the texture of the extracellular matrix. Standardised bone defects were created in the lower jaw of 10 adult minipigs. These defects were reconstructed with a pasty calcium-phosphate cement mixture. After a healing time of 4 months, the animals were sacrificed. The mandibles of all animals were resected and non-decalcified histological sections of the areas of interest were prepared. The experiment was evaluated by means of qualitative histology and histomorphometry. The hydroxyapatite cement entirely hardened intraoperatively. Modelling and handling of the cement was facile and the margin fit to the host bone was excellent. Histology showed that resorption started in the periphery and proceeded exceptionally fast. The bony substitution, especially in phosphoserine-endowed cements, was very promising. After a healing period of 4 months, phosphoserine cements showed a bone regeneration of nearly two-thirds of the defect sizes. In the applied animal experiment, the newly developed hydroxyapatite collagen-I cement is well suited for bone substitution due to its easy handling, its excellent integration and good resorption characteristics. The addition of phosphoserine is very promising in terms of influencing resorption features and bone regeneration.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany. Ronald.Mai@uniklinikum-dresden.de
authors.forename: Ronald
authors.initials: R
authors.lastname: Mai
authors.forename: Romy
authors.initials: R
authors.lastname: Lux
authors.forename: Peter
authors.initials: P
authors.lastname: Proff
authors.forename: Günter
authors.initials: G
authors.lastname: Lauer
authors.forename: Winnie
authors.initials: W
authors.lastname: Pradel
authors.forename: Henry
authors.initials: H
authors.lastname: Leonhardt
authors.forename: Antje
authors.initials: A
authors.lastname: Reinstorf
authors.forename: Michael
authors.initials: M
authors.lastname: Gelinsky
authors.forename: Roland
authors.initials: R
authors.lastname: Jung
authors.forename: Uwe
authors.initials: U
authors.lastname: Eckelt
authors.forename: Tomasz
authors.initials: T
authors.lastname: Gedrange
authors.forename: Bernd
authors.initials: B
authors.lastname: Stadlinger
mesh_terms: D000818:Animals; D001843:Bone Cements / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D024042:Collagen Type I / Q000627:therapeutic use*; D017102:Fracture Healing / Q000187:drug effects*; D008337:Mandibular Fractures / Q000473:pathology* / Q000628:therapy*; D010768:Phosphoserine / Q000627:therapeutic use*; D013552:Swine; D013556:Swine, Miniature; D016896:Treatment Outcome
chemical_list: D001843:Bone Cements; D002130:Calcium Phosphates; D024042:Collagen Type I; D010768:Phosphoserine; C020243:calcium phosphate